Vivus’ Qsymia beats out weight loss com­peti­tors in pric­ing watch­dog's lat­est cost-ef­fec­tive­ness analy­sis

Cost-ef­fec­tive­ness watch­dog ICER took a look at sev­er­al dif­fer­ent drugs ap­proved for obe­si­ty and weight loss — and to them, there is a clear win­ner.

ICER de­ter­mined that Vivus’ Qsymia, the brand name for the ap­petite sup­pres­sant phen­ter­mine com­bined with the an­ti­con­vul­sant top­i­ra­mate, was more cost ef­fec­tive for weight loss than oth­er com­peti­tors such as No­vo Nordisk’s Sax­en­da and We­govy.

“When treat­ments were com­pared with each oth­er, phen­ter­mine/top­i­ra­mate plus lifestyle mod­i­fi­ca­tion was less cost­ly and more ef­fec­tive than bupro­pi­on/nal­trex­one plus lifestyle mod­i­fi­ca­tion,” the re­view­ers said in their analy­sis.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER